Serum NfL Levels and PML Risk in MS Patients Treated With Natalizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neurology(R) Neuroimmunology & Neuroinflammation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
Neurol Neuroimmunol Neuroinflamm 2021 Jul 01;8(4)e1003, N Fissolo, B Pignolet, J Rio, P Vermersch, A Ruet, J deSèze, P Labauge, S Vukusic, C Papeix, L Martinez-Almoyna, A Tourbah, P Clavelou, T Moreau, J Pelletier, C Lebrun-Frenay, B Bourre, G Defer, X Montalban, D Brassat, M ComabellaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.